Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
57
resultados
Última actualización
25/10/2026 [06:45:00]
Resumen de: US20260327334A1
The present disclosure relates to combination dosing regimen comprising an anti-KMA antibody, an IMiD/CELMOD and a steroid. Such combinations may be used for the treatment of multiple myeloma.
Resumen de: US20260325562A1
Provided according to embodiments of the invention are methods of treating a disorder in a subject in need thereof that include administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject. In some embodiments of the invention, the disorder is a hyperproliferative disorder such as a cancer. In some embodiments, the disorder is a hematological cancer such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), leukemia (e.g., acute myeloid leukemia), or lymphoma.
Resumen de: US20260327304A1
The present disclosure provides an antibody capable of binding to LILRB4 and a bispecific antibody capable of binding to LILRB4 and CD3. Further provided are a nucleic acid molecule encoding the antibodies, an expression vector for use in expressing the antibodies, a host cell, and a method. The present disclosure also relates to a method for treating a solid tumor, multiple myeloma, or leukemia such as acute myeloid leukemia (AML) using the anti-LILRB4×CD3 bispecific antibody of the present disclosure.
Resumen de: US20260327331A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Resumen de: US20260325545A1
0000 Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma.
0000
Resumen de: US20260325633A1
At this invention I presents medication to leukemia and cancer/tumors.
Resumen de: US20260327717A1
The invention features methods for the identification of genomic aberrations in circulating tumor cells isolated from peripheral blood. In embodiments, the methods involve isolation of a small number of purified circulating multiple myeloma cells, purification of genomic DNA from the cells, and sequencing of the genomic DNA.
Resumen de: WO2025128434A1
The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.
Resumen de: US20260315486A1
0000 The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Resumen de: AU2025251398A1
The present invention relates to immunosuppressive compounds that deplete coronin 1 levels, in particular to coronin 1 promoter inhibitors. Accordingly, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, or solvate thereof. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.
Resumen de: US20260317835A1
0000 There are provided methods for detecting and classifying a B-cell malignancy selected from the group consisting of a B-cell lymphoma, a B-cell leukemia, and a plasma cell dyscrasia in a subject. The methods employ a tumor cell profiling algorithm to analyze single-cell RNA sequencing data obtained from a sample of, e.g., the subject's blood or bone marrow, enriched for a cell type comprising tumoral cells using a cell surface marker. This algorithm identifies one or more one or more expanded clonal cell populations and categorizes each of the one or more expanded clonal cell populations as malignant or pre-malignant tumor cell population if expression of one or more malignancy markers is detected. The one or more malignant or pre-malignant tumor cell population(s) can be analyzed using a statistical model or machine learning algorithm to classify the B-cell malignancy.
Resumen de: WO2026217529A1
The disclosure herein provides compositions for the treatment of cancer. In some embodiments, the method of treating cancer comprising: administering to a subject in need thereof celastrol and one or more additional agents selected from: simvastatin; fluoxetine; memantine; auranofin; colchicine; adefovir; pyrvinium; digoxin; fluvastatin; doxepin; and gemcitabine. In some embodiments, the disclosure provides compositions for the treatment of lung cancer, breast cancer, colorectal cancer, skin cancer, brain cancer, leukemia, pancreatic cancer, esophageal cancer, cervical cancer, head and neck cancer, or ovarian cancer.
Resumen de: US20260315461A1
0000 The present invention relates to a compound of formula (I), or any of its pharmaceutically acceptable salt:
0000
0000 wherein R<1 >represents a halogen atom, a (C<1>-C<6>)alkyl group, a (C<3>-C<6>)cycloalkyl group, a (C<2>-C<6>)alkenyl group, a (C<1>-C<6>)alkoxy group or a (C<3>-C<6>)cycloalkoxy group, X and Y independently represent a —CH═ group, a —CR<3>═ group or a —N═ group, Z1 and Z2 independently represent a —CH<2>— group, a ═CH— group or a ═N— group and R<3 >and R<4 >independently represent a hydrogen atom or a halogen atom.
0000 It further relates to such a compound for its use as a medicament, and in particular for its use in treating and/or prevention of cancer, in particular cancer exhibiting recruitment of MDM2 to chromatin, more particularly selected from the group consisting of bone cancer, brain cancer, ovary cancer, breast cancer, lung cancer, colorectal cancer, osteosarcoma, skin cancer, blood cancer, including acute myeloid leukemia, pancreatic cancer, prostate cancer and liposarcoma and even more particularly selected from the group consisting of skin cancer, blood cancer, for example but not limited to acute myeloid leukemia, melanoma and liposarcoma.
Resumen de: WO2025122791A1
Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.
Resumen de: WO2025120113A1
Provided herein are methods of treating and/or managing multiple myeloma, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione ("Compound A"), or an enantiomer or a mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a bispecific antibody comprising a first binding part binding to B cell maturation antigen (BCMA) and a second binding part binding to cluster of differentiation 3 (CD3).
Resumen de: WO2025122985A1
Provided herein are methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine. Also provided herein are methods of inhibiting/overcoming resistance of AML to venetoclax in a subject in need thereof, and/or improving the efficacy of venetoclax in the treatment of AML in a subject in need thereof, comprising administering to the subject combinations of Compound 1, or a pharmaceutically acceptable salt thereof, venetoclax, and 5-azacitidine.
Resumen de: EP4821917A1
0001 A compound represented by formula (I) as a PCNA inhibitor, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof, a preparation method therefor, an intermediate compound thereof, a pharmaceutical composition thereof and the use thereof. The PCNA inhibitor and the pharmaceutical composition comprising same can be used for treating cancers, comprising lung cancer, melanoma, colon cancer, rectal cancer, prostate cancer, ovarian cancer, leukemia, etc with PCNA overexpression.
Resumen de: EP4821484A1
0001 The present disclosure relates to a composition, which can be a lyophilization preparation liquid or a lyophilized powder preparation. The composition comprises a multispecific antibody, a surfactant, a buffer system, and a stabilizer/a osmotic pressure regulator. Further disclosed are a preparation method and use of the composition, for example use in the treatment of a tumor, in particular multiple myeloma.
Resumen de: US20260308541A1
0000 The present invention relates to reverse transcriptase enzymes comprising a modified Moloney Murine Leukaemia Virus reverse transcriptase amino acid sequence, wherein said amino acid sequence comprises a mutation compared to the wild-type Moloney Murine Leukaemia Virus reverse transcriptase, and said enzyme possesses increased inhibitor resistance compared to the wild-type Moloney Murine Leukaemia Virus reverse transcriptase. The present invention also relates to compositions, reaction mixtures, and kits comprising the said reverse transcriptase enzymes are used to synthesize cDNA from RNA.
Resumen de: WO2026213556A1
The present disclosure is concerned with pharmaceutical compositions comprising an inosine-5' -monophosphate dehydrogenase 2 (IMPDH2) inhibitor and methods of treating cancer (e.g., a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: WO2026213197A1
The present invention relates to lH-pyrazolo3,4-bpyridine compounds and methods useful as inhibitors of HRI kinase for the treatment or prevention of hematological disorders The invention includes a method of treating myelodysplastic syndrome in patients who are non-responders to luspatercept or elythropoiesis-stimulating agents comprising the administration, to a patient in need thereof, of a HRI kinase inhibitor.
Resumen de: WO2026213527A1
The present invention provides methods and compositions for using a piperidinyl-methylpurineamine nuclear SET domain- containing protein 2 (NSD2) inhibitor to treat light chain myeloma in subjects with reduced activity of the TP53 gene or elevated expression of NSD2 due to a medical defect other than a t(4; 14) translocation.
Resumen de: US20260308226A1
The present invention provides NK cell compositions and/or preparations and methods of using such NK cell compositions and/or preparations for immunotherapy. The NK cell compositions and/or preparations can be used in therapies of a broad range of viral infections, bacterial infections, cancer and leukemia malignancies, and other diseases.
Resumen de: US20260308130A1
0000 A genus of bicyclic inhibitors of CBX chromodomains is disclosed. The compounds are of the following genus:
0000
0000 The compounds inhibit CBX proteins and, as a consequence, they are useful for treating prostate cancer, ovarian cancer, and B-cell lymphoma.
Nº publicación: US20260306486A1 08/10/2026
Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES [US]
SLOAN KETTERING INST FOR CANCER RESEARCH [US]
BIOSPLICE THERAPEUTICS INC [US]
Memorial Sloan-Kettering Cancer Center
Memorial Hospital for Cancer and Allied Diseases
Sloan-Kettering Institute for Cancer Research
Biosplice Therapeutics, Inc.
Resumen de: US20260306486A1
The present disclosure provides methods for treating leukemia (e.g., AML) using a CLK/DYRK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor (e.g., venetoclax). Kits for use in practicing the methods are also provided.
BOPI
Sede Electrónica
